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Abstract
We conducted a phase I study of alemtuzumab combined with CHOP (cyclophosphamide, adriamycin,
vincristine and prednisone) chemotherapy in peripheral T cell lymphomas. The objectives were to establish the
safest dose with the highest antibody levels and evaluate the effects on the immune system. Twenty patients
were enrolled across 4 dose levels. Maximally tolerated dose was not reached with alemtuzumab 60 mg
subcutaneously every 3 weeks and antibody levels were highest at this dose level. The results of this study
inform other investigators about possibilities for optimal dosing in T cell lymphomas when used in combination
with chemotherapy and highlight the high levels of baseline and post-treatment immune suppression observed
in this patient group.
Background: Alemtuzumab has single-agent activity in relapsed peripheral T cell lymphoma (PTL), but the optimal
dose and/or schedule in combination with chemotherapy for ﬁrst-line use is unknown. The primary objectives were to
establish the maximally tolerated dose and pharmacokinetics (PK) of alemtuzumab combined in this way. Patients
and Methods: Adult patients with untreated CD52-positive (CD52þ) PTL were enrolled in a phase I trial. Alemtuzumab
was given subcutaneously in escalating doses and/or schedules in combination with CHOP (cyclophosphamide,
adriamycin, vincristine and prednisone) using a 3þ3 design. Trough PK of alemtuzumab were measured on day 1 of
each 21-day cycle and B and T cell subsets were serially measured. Results: Twenty patients were enrolled across 4
dose levels. Dose-limiting toxicities necessitated expansion at 10 mg weekly (fatal tuberculosis reactivation) and 60
mg every 3 weeks (grade 4 thrombocytopenia) dose levels. Maximally tolerated dose was not reached. Ten patients
developed asymptomatic cytomegalovirus reactivations at a median of 39 days (range, 4-99 days). Two patients
developed fungal pneumonias. The overall and complete response rates were 68% and 37%, respectively. Highest
day 1 alemtuzumab trough levels were achieved at 60 mg (1973 ng/mL), but with signiﬁcant inter- and intradose
variability. Lymphopenia at baseline was common and T cell recovery was signiﬁcantly delayed. Conclusion: With
monitoring and prophylaxis, alemtuzumab 60 mg combined with CHOP showed activity in CD52þ PTL and achieved
the highest drug levels.
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Introduction
The mature T-cell and natural killer (NK)-cell neoplasms are
uncommon heterogeneous lymphoid cancers that comprise 10% to
15% of all aggressive lymphomas.1 Historically, clinical outcomes of
T cell lymphoma patients who receive CHOP (cyclophosphamide,
adriamycin, vincristine and prednisone)-like regimens have been
inferior to those of patients with B cell lymphoma with this disparity
magniﬁed by the advent of anti-CD20 chemoimmunotherapy. The
reported 5-year overall survival (OS) rates for mature T cell lym-
phomas are 32% to 37% in international registries2,3 with minimal
improvement despite schedule intensiﬁcation and the combination of
etoposide.4 No published randomized trials exist for peripheral T cell
lymphoma (PTL) because of its rarity and diverse subtypes and the
role for upfront consolidative high dose therapy with autologous stem
cell transplant is inconclusive.5-8 Because of the poor outcomes with
initial therapy for T-cell lymphomas, novel therapies and approaches
need to be tested.
Alemtuzumab is a humanizedmurinemonoclonal antibody directed
against the antigen CD52, a 21- to 28-kD cell-surface glycoprotein
found on 95% of normal B and T lymphocytes, monocytes, and eo-
sinophils, but not on human hematopoietic progenitor cells.9,10 Clin-
ical activity of alemtuzumab monotherapy has been observed in
relapsed chronic lymphocytic leukemia (CLL),11-13 T-cell prolym-
phocytic leukemia,14-16 mycoses fungoides/Sézary syndrome,17 and
relapsed refractory peripheral T cell lymphoma (PTL).18 With no
previous pharmacokinetics (PK) studies to inform dose, schedule, or
safety, we performed a phase I dose escalation study of alemtuzumab in
combination with CHOP in patients with previously untreated PTL.
The primary objectiveswere to establish themaximumtolerated dose of
combination therapy and the trough PK of alemtuzumab in different
subcutaneous doses and schedules. The secondary objectives were to
examine efﬁcacy and the effects on T cell reconstitution, immuno-
globulins, and cytomegalovirus (CMV) reactivation.
Patients and Methods
Study Design
This was a multicenter phase I study coordinated through the
Ontario Clinical Oncology Group (OCOG). The study was
approved by all center research ethics boards and participating
patients provided written informed consent. See Appendix A in the
online version at http://dx.doi.org/10.1016/j.clml.2015.11.008 for
further details.
Patients
Patients  18 years of age with untreated, histologically proven,
CD52-positive (CD52þ) T cell lymphomas were eligible. Patients
had measureable stage II to IV disease, a life expectancy of at least
16 weeks, an Eastern Cooperative Oncology Group performance
status <3 and adequate hematologic, renal, and liver function. The
following lymphoma subtypes were eligible: PTL not otherwise
speciﬁed (NOS), angioimmunoblastic T cell lymphoma (AITL),
anaplastic lymphoma kinase-1 negative (ALK1) anaplastic large
cell lymphoma (ALCL), hepatosplenic, enteropathy-associated, and
subcutaneous panniculitic T cell lymphomas.19 Patients with HIV,
central nervous system involvement at baseline, Sézary syndrome, or
human T-cell lymphotropic virus-1 associated or natural killer(NK)/T cell histologies were excluded. All patients had conﬁrmation
of expression of CD52 according to immunohistochemistry (IHC)
performed at a central laboratory20,21 (see Appendix A in the online
version at http://dx.doi.org/10.1016/j.clml.2015.11.008). To
increase patient accrual, the protocol was amended after the
completion of dose level 2 to permit up to 1 cycle of CHOP
chemotherapy for those with rapidly progressive disease who
required treatment while awaiting conﬁrmation of CD52 positivity.
Methods
CHOP chemotherapy was given at standard doses (see Appendix A
in the online version at http://dx.doi.org/10.1016/j.clml.2015.11.008)
for 6 to 8 cycles repeated every 21 days for up to 8 cycles. Treatment
with subcutaneous alemtuzumab occurred at increasing dose levels
using a standard 3þ3 design: (1) 10 mg on day 1; (2) 10mg on days 1,
8, and 15; (3) 30 mg on day 1; (4) 60 mg on day 1; and (5) 30 mg on
days 1, 8, and 15. Three patients were sequentially enrolled at a given
dose level. Dose-limiting toxicities (DLTs) were deﬁned as: Grade3
neutropenia during granulocyte colony stimulating factor (GCSF)
treatment by day 1 of the next cycle, platelet count of<10 109/L at
any time or<50 109/L by day 1 of the next cycle, death during the
study, febrile neutropenia exceeding 10 days’ duration, any Grade 3
infection attributed to study drugs, any nonhematologic toxicity of
Grade 3 (excluding nausea, vomiting, and alopecia) likely related to
study medication, and any interruption of study medicine because of
toxicity that exceeded 14 days. If noDLTs were observed by the end of
cycle 3, enrollment at the next dose level proceeded. If 1 of 3 patients
experienced a DLT before the end of cycle 3, an additional 3 patients
were enrolled at that dose level.
Cytomegalovirus reactivation in the absence of overt infection
was not considered a DLT. The maximally tolerated dose of this
drug combination was deﬁned as the dose level below the one in
which escalation was stopped because of DLTs.
Therapy was discontinued in case of progressive lymphoma,
physician discretion, DLT, or consent withdrawal. For the purpose
of safety assessment the treatment period included the time from the
ﬁrst dose of alemtuzumab until 8 weeks after the ﬁnal cycle of
CHOP chemotherapy (see Appendix A in the online version at
http://dx.doi.org/10.1016/j.clml.2015.11.008).
Anti-Infective Prophylaxis
Prophylaxis for herpes simplex virus, varicella zoster virus, and
pneumocystis jerovecii (PJP) included famciclovir and
sulfamethoxazole-trimethoprim (see Appendix A in the online
version at http://dx.doi.org/10.1016/j.clml.2015.11.008).
Evaluations During Study
Clinical. Baseline staging included a physical examination, com-
plete blood count (CBC), electrolyte levels, hepatic and renal
function tests, lactate dehydrogenase level, serologic testing for
CMV immunoglobulin G antibody, computed tomography (CT)
scanning, and bone marrow trephine biopsy. A lumbar puncture
was done if clinically indicated. Patients were assessed every 3 weeks
with repeat CBC, and renal and hepatic blood tests. After chemo-
therapy was completed, patients were assessed every 3 months for 2
years and then every 6 months until 5 years.Clinical Lymphoma, Myeloma & Leukemia January 2016 - 19
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20 -Cytomegalovirus Monitoring. Cytomegalovirus monitoring was
performed every 2 weeks, initially using enzyme-linked immuno-
sorbent assay (ELISA; pp65 antigen) and then using polymerase
chain reaction (PCR) analysis after August 2008 (see Appendix A in
the online version at http://dx.doi.org/10.1016/j.clml.2015.11.
008). Any conﬁrmed asymptomatic CMV antigenemia was
treated pre-emptively with oral valganciclovir 450 mg orally twice
per day for 2 weeks until biweekly CMV monitoring was negative
for 2 consecutive readings. Patients who developed clinical signs or
symptoms of overt CMV infection (retinitis, pneumonitis, enteritis)
with conﬁrmed CMV in antigen testing, were considered to have
experienced a DLT and removed from the study.
Immunologic Analyses. At baseline, all patients underwent serum
quantitative immunoglobulin testing, which was repeated every 6Figure 1 Study Flow Diagram
Abbreviations: chemo ¼ chemotherapy; CNS ¼ central nervous system; G4 ¼ grade 4; OS ¼ ove
Clinical Lymphoma, Myeloma & Leukemia January 2016months for 2 years during the study. T- and B-cell subset analysis was
done at baseline and at 3, 6, and 12 months after study enrollment.
Efﬁcacy Deﬁnitions
After the third and the ﬁnal alemtuzumab-CHOP cycles, patients
were restaged according to CT scans and responses deﬁned ac-
cording to 1999 International Working Group guidelines of Che-
son et al.22 In the absence of overt progressive disease, restaging CT
scans continued every 6 months for 2 years. OS and progression-free
survival (PFS) were deﬁned from time of enrollment.
Pharmacokinetics
Predose (trough) levels were drawn on day 1 of every cycle.
Where possible, kinetics of elimination were determined after
termination of alemtuzumab therapy from plasma samples drawnrall survival; PFS ¼ progression-free survival; TB ¼ tuberculosis.
Table 1 Baseline Characteristics (n [ 20)
Characteristic Value
Median Age at Time of Diagnosis
(Range)
55.3 (22.7-76.8)
Male Sex 15 (75.0)
ECOG Performance Status
0 7 (35.0)
1 11 (55.0)
2 1 (5.0)
3 1 (5.0)
Median LDH, U/L (Range) (n[ 18) 227 (125-1111)
Treatment Dose
10 mg Q3 weekly (10 mg) 3 (15.0)
10 mg weekly (10 mg  3) 6 (30.0)
30 mg Q3 weekly (30 mg) 5 (25.0)
60 mg Q3 weekly (60 mg) 6 (30.0)
Histology
Peripheral T-cell lymphoma, NOS 6 (30.0)
Angioimmunoblastic (AILD) 7 (35.0)
ALK1 anaplastic 3 (15.0)
Hepatosplenic 1 (5.0)
Enteropathy-associated 1 (5.0)
Panniculitic 2 (10.0)
Ann Arbor Stage
2 3 (15.0)
3 6 (30.0)
4 11 (55.0)
Extranodal Sites
n (%) with 1 13 (65.0)
Median number of sites (Range) 1 (0-3)
Sites of Extranodal Disease
Liver 4 (20.0)
Lung 4 (20.0)
Bone Marrow 11 (55.0)
Skin 1 (5.0)
Other (jejunum, mesentery/
peritoneum)
2 (10.0)
Received Previous CHOP for 1
Cycle
4 (20.0)
Presence of B Symptoms 8 (40.0)
IPI (n [ 18)
Low (0-1) 7 (38.9)
Low-Intermediate (2) 4 (22.2)
High-Intermediate (3) 4 (22.2)
High (4-5) 3 (16.7)
Data are presented as n (%), except where otherwise noted.
Abbreviations: AILD ¼ angioimmunoblastic lymphoma; ALK ¼ anaplastic lymphoma kinase;
CHOP ¼ cyclophosphamide, adriamycin, vincristine and prednisone; ECOG ¼ Eastern Coop-
erative Oncology Group; IPI ¼ International Prognostic Index; LDH ¼ lactate dehydrogenase;
NOS ¼ not otherwise speciﬁed; Q3 ¼ every 3 weeks.
Rena Buckstein et altwice weekly for 2 weeks (see Appendix A in the online version at
http://dx.doi.org/10.1016/j.clml.2015.11.008).
Toxicity. Adverse events (AEs) were reviewed using the Common
Terminology Criteria for Adverse Events Version 3.0 (CTCAE
v3.0; see Appendix A in the online version at http://dx.doi.org/10.
1016/j.clml.2015.11.008).
Statistics
Sample Size. Using the modiﬁed Fibonacci phase I design,23
cohorts of 3 patients at each dose level were enrolled. The mini-
mum sample size would be 15 patients and the maximum 30.
Although the intention was to expand the maximum tolerated dose
(MTD) for phase II testing, the study was closed after phase I
completion of dose level 4 because of slow accrual.
Analysis
Data were analyzed descriptively using SAS version 9.2 (SAS
Institute, Cary, NC) and R version 2.13.1 (www.r-project.org). OS
and PFS curves were calculated using the KaplaneMeier method.24
All evaluations were 2-sided and a P value of  .05 was considered
statistically signiﬁcant (see Appendix A in the online version at
http://dx.doi.org/10.1016/j.clml.2015.11.008).
Results
Between November 2006 and December 2012, 44 patients were
screened and 20 patients were enrolled, at a median time from
diagnosis of 1.8 months (range, 0.2-14 months). Follow-up data
until April 11, 2014 are presented (Figure 1). The median age was
55 (range, 23-77) years, 85% had advanced stage disease and 65%
had extranodal involvement (Table 1). Of 29 patients who con-
sented to screening of their biopsy specimens for CD52 expression,
9 (31%) were negative (Figure 1). One patient was deemed ineli-
gible for response or survival after cycle 2 when central pathology
review disclosed the presence of AITL and diffuse large B cell
lymphoma.
Four patients (20%) received a single cycle of CHOP chemo-
therapy before study enrollment. The median number of cycles of
CHOP-alemtuzumab was 6 (range, 2-8) with only 6 patients who
completed all 8 cycles. A total of 122 cycles were given with a
median cycle length of 21 days (range, 19-48 days). The median
cumulative dose of alemtuzumab received was 185 mg (range,
60-420 mg), with medians of 60, 205, 180, and 270 mg at dose
levels 1 through 4, respectively (Table 2).
Toxicity
Twenty patients were evaluable for toxicity (according to dose
level, shown in Table 3). There were 14 patients (70%) with Grade
3 to 4 neutropenia and 4 (20%) with Grade 3 to 4 thrombocyto-
penia overall, but 50% with Grade 3 to 4 thrombocytopenia at the
highest alemtuzumab dose level. Most nonhematological toxicities
were Grade 2 and infectious. There were 6 episodes of febrile
neutropenia in 4 patients. Eleven patients (55%) received GCSF
and 1 patient experienced Grade 3 bacterial pneumonia.
Ten patients (50%) developed asymptomatic CMV reactivation
(n¼ 9) or new infection (n¼ 1) at a median time of 39 days (range,4-99 days); 1 patient had a second CMV reactivation and 2 had 3
reactivations. Patients whose CMV reactivated more than twice
were given pre-emptive valganciclovir until completion of therapy.Clinical Lymphoma, Myeloma & Leukemia January 2016 - 21
Table 2 Outcomes
Outcome n Value
Number of Cycles,
CHOP
20 6 (2-8)
Number of Cycles,
Alemtuzumab
20
2 2 (10)
3 2 (10)
4 2 (10)
5 1 (5)
6 5 (25)
7 2 (10)
8 6 (30)
Cumulative Dose,
Alemtuzumab
20 185 (60-420)
Dose Level 1 3 60 (60-80)
Dose Level 2 6 205 (60-240)
Dose Level 3 5 180 (60-240)
Dose Level 4 6 270 (180-420)
Duration of Response,
Months
13 19.1 (3.3-44.2)
Duration of
Follow-Up, All
Patients, Months
20 28.4 (1.3-77.4)
Duration of
Follow-Up, Patients
Alive at Last
Follow-Up, Months
15 35.8 (16.0-77.4)
Best Response, All
Patients,
CR:CRu:PR:SD:PD:NE/
Dead
20 4:3:6:1:4:2
Dose Level 1 3 1:0:2:0:0:0
Dose Level 2 6 1:1:1:0:2:1
Dose Level 3 5 1:1:0:1:1:1
Dose Level 4 6 1:1:3:0:1:0
Overall Survival 19
Events, n (%) 4
Median, months Not reached
2-Year (95% CI) 78.9% (62.6%-99.6%)
Progression-Free
Survival
19
Events, n (%) 10 (52.6%)
Median, months 23.4
2-Year (95% CI) 47.5% (28.6%-75.6%)
Values are presented as n (%) or median (range) except where otherwise noted.
Abbreviations: CHOP ¼ cyclophosphamide, adriamycin, vincristine and prednisone; Cru ¼
complete remission unconﬁrmed; NE ¼ not evaluable.
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22 -The median time of valganciclovir treatment was 44 days (range,
14-151 days). No patient developed overt CMV disease. One
patient in dose level 4 with asymptomatic CMV reactivation
developed increasing CMV titers during valganciclovir treatment
because of the acquisition of viral UL97 and UL54 resistance
mutations and required treatment with intravenous (I.V.) foscarnet.
This patient received only 4 cycles of CHOP-alemtuzumab and 2
additional cycles of CHOP alone.Clinical Lymphoma, Myeloma & Leukemia January 2016Two cases of Grade 3 fungal pneumonia were documented, 1 in
the setting of febrile neutropenia (dose level 2, cycle 8, associated
with cryptococcal cellulitis) and another 3 weeks after cycle 7 (dose
level 4, bronchoscopy biopsy was positive for invasive fungi, culture
was negative). Both were successfully treated.
Dose-Limiting Toxicity
There were 2 DLTs necessitating expansion of dose levels 2 and
4. In dose level 2, a 62-year-old Asian man with subpanniculitic
lymphoma developed fulminant tuberculosis hepatitis and pneu-
monitis after 2 cycles of CHOP-alemtuzumab and succumbed from
liver failure after an inability to tolerate isoniazid/rifampin. The
second DLT at dose level 4 occurred in a patient with baseline
Grade 2 thrombocytopenia (platelet count, 52  109/L), who
experienced persistent Grade 4 thrombocytopenia after 3 cycles of
alemtuzumab/CHOP chemotherapy. He completed 3 additional
cycles of dose-reduced CHOP alone.
Response
Of the 19 response-evaluable patients, 7 (37%) achieved com-
plete response or complete remission unconﬁrmed, 6 (32%) partial
response, 1 (5%) stable disease, and 1 (5%) died (according to dose
level, see Table 2). The median duration of response was 19 months
(range, 3-44 months). Four patients had primary progressive disease
at a median time of 4.1 months (range, 2.7-5.7 months). With a
median follow up of 28 months (range, 1.3-77.4), 9 patients (50%)
had relapsed or had disease progression, and 4 (21%) had died.
Actuarial 2-year PFS, and OS were 47.5% (95% conﬁdence interval
[CI], 28.6%-79.0%), and 78.9% (95% CI, 62.6%-99.6%;
Figure 2).
Immune Parameters
B- and T-cell subsets over time are shown in Figure 3. Eight of
17 patients (47%) with absolute lymphocyte count (ALC) measured
before chemotherapy had an ALC of < 1.0  109/L. Notably,
50%, 71%, 93%, and 50% of patients had lower than normal
CD19þ, CD3þ, CD4þ, and CD8þ cell counts, respectively at
baseline. T cell depletion was profound until the 6-month mark,
when recovery in all T-cell subsets began, although only 45% of
patients recovered or surpassed baseline CD3þ levels by 10 to 12
months. Recovery to baseline CD4þ T cells by 12 months was seen
in only 20% of patients, and recovery of CD8þ T cells was seen in
73% of patients. In contrast, B cell recovery began earlier and
surpassed baseline in 89% of patients. NK cell levels (reduced in
35% at baseline) declined during the study but recovered to baseline
or higher in 80%. When immunoglobulins were measured serially
at least three times, increases were seen in 11 patients (see
Supplemental Figure 1 in the online version at http://dx.doi.org/10.
1016/j.clml.2015.11.008). Most patients had declines in their
serum immunoglobulins of 40% to 80%, with less than half who
recovered to their baseline levels at 1 year. Nevertheless, most
immunoglobulin measurements remained within the normal refer-
ence ranges.
Pharmacokinetics
Trough levels of alemtuzumab measured on day 1 of every cycle
for patients who remained in 3 or more cycles were evaluable in 17
Table 3 Adverse Events According to CTCAE
Adverse Event Grade 2 3 4 5
Dose Level 1 [ 10 mg (n [ 3)
Febrile neutropenia e 1 e e
Varicella zoster 1 e e e
Nausea/vomiting 1 e e e
Neuropathy 1 e e e
Mucositis 1 e e e
Pain 1 e e e
Leukopenia e 1 e
Lymphopenia 1 2 e
Neutropenia 2 1 e
Dose Level 2 [ 10 mg 3 3 (n [ 6)
Febrile neutropenia 1 e e e
CHF; CAS 1 e e e
Constipation e 1 e e
Cryptoccus right lower limb e 1 e e
BK cystitis e 1 e e
Cellulitis 1 e e e
Dyspnea e 2 e e
Increased ALP/AST levels e 1 e e
Hyperglycemia e 1 e e
Infection and fever
(Hickman)
e 1 e e
Cryptococcal pneumonia e 1 e e
Bacterial pneumonia e 1 e e
Hepatic failure (TB) e e e 1
Varicella zoster 1 e e e
Mucositis 1 e e e
Neuropathy 1 e e e
Nausea/vomiting 1 e e e
Depression 2 e e e
Fatigue 3 e e e
Anemia 1 1 e e
Leukopenia e 1 1 e
Lymphopenia e e 1 e
Neutropenia 1 1 1 e
Dose Level 3 [ 30 mg (n [ 5)
Hyperglycemia e 1 e e
Peripheral neuropathy e 1 e e
Fatigue 2 e e e
Iritis 1 e e e
Neuropathy 1 e e e
Pain 2 e e e
Vomiting 1 e e e
Dyspnea 1 e e e
Anemia 1 1 e e
Leukopenia e 1 2 e
Lymphopenia e 1 4 e
Neutropenia 1 1 2 e
Thrombocytopenia e e 1 e
Rena Buckstein et al
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Table 3 Continued
Adverse Event Grade 2 3 4 5
Dose Level 4 [ 60 mg (n [ 6)
Hyponatremia e 1 e e
Febrile neutropenia e 2 e e
Cystitis 1 e e e
Pain 4 e e e
Pneumonia e 1 e e
Bacterial infection 2 e e e
Nausea/vomiting 1 e e e
Constipation 2 e e e
Dyspnea e 1 e e
Anemia e 1 2 e
Leukopenia 1 1 4 e
Lymphopenia e 1 5 e
Neutropenia e 1 5 e
Thrombocytopenia 1 1 2 e
Abbreviations: ALP ¼ alkaline phosphatase; AST ¼ aspartate aminotransferase; BK ¼ BK virus; CAS ¼ coronary artery syndrome; CHF ¼ congestive heart failure; CTCAE ¼ Common Terminology
Criteria for Adverse Events; TB ¼ tuberculosis.
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24 -patients and ranged from 41.7 ng/mL to 1973 ng/mL with the
median highest trough levels of 307 ng/mL (Figure 4). Only 3
patients achieved trough levels that exceeded 1000 ng/mL, and 2
were treated at the highest dose level. Because we primarily
measured trough levels of alemtuzumab we did not have the data to
observe a 2-compartment model previously reported.24,25 We did
observe a large variability in concentrations between patients at each
dose level of at least fourfold, as had been observed by others in
CLL.24,25 Although trough levels appeared to increase with
increasing doses in most instances, there was no discernable rela-
tionship between maximum trough concentrations and response
(197.6 ng/mL for relapse and/or disease progression vs. 388.1
ng/mL for durable response; P ¼ .7239; see Supplemental Figure 2
in the online version at http://dx.doi.org/10.1016/j.clml.2015.11.
008). Estimated terminal half-life (measurable in 8 patients) was a
median of 12 days (range, 3.5-58 days).
Discussion
In this phase I study, the safety, PK, efﬁcacy, and immunological
effects of combining alemtuzumab in various doses and schedules
with CHOP chemotherapy for patients with aggressive CD52þ T
cell lymphomas were evaluated. The maximum dose level tested was
60 mg subcutaneously (S.C.) on day 1 every 21 days, and this dose
level was tolerable and resulted in the highest trough antibody levels.
PK were nonlinear, with high interdose and patient variability. This
combination was immunosuppressive and we observed a high rate
of CMV reactivation and documented pneumonia (2 fungal, 1
bacterial). Almost half of the patients (47%) enrolled in this study
were lymphopenic at baseline and T-cell reconstitution was delayed
and incomplete at 1 year.
With evidence that alemtuzumab has single agent activity in
relapsed PTL (overall response rate, 36%),18 other groups have com-
bined alemtuzumab with different forms and schedules of cytotoxic
chemotherapy for the management of relapsed/refractory18,26-29 orClinical Lymphoma, Myeloma & Leukemia January 2016newly diagnosed29-35 disease. In these studies, the alemtuzumab dose
and/or schedule was arbitrarily selected and with the exception of 2
studies,30,34 CD52 expression was not determined before treatment.
There is only 1 previous unpublished phase I study of I.V. alemtu-
zumab in doses that ranged from 30 to 90 mg combined with dose-
adjusted EPOCH (etoposide, prednisone, vincristine, cyclophospha-
mide, and adriamycin). In this National Cancer Institute (NCI) study
of 14 patients, 30 mg I.V. every cycle was the dose recommended for
phase II testing because of excessive bonemarrow suppression observed
at the higher doses.30We also observed the highest rates of Grades 3 to
4 thrombocytopenia and neutropenia at dose level 4 (1 Grade 4
thrombocytopenia was a DLT), but in contrast to results of the NCI
study, the MTD was not reached at 60 mg. Possible explanations for
these differences could include the different routes of alemtuzumab
administration (I.V. vs. S.C.) and toxicities of the selected chemo-
therapy regimens.36 In the recently enrolled alemtuzumab and CHOP
in T-cell lymphoma (ACT1e) and ACT-2 studies (randomized
controlled trials that compared CHOP-14 with CHOP-14 with
alemtuzumuab), an early dose reduction from 360mg of alemtuzumab
(30mg for days 1-2 of CHOP-14) to 120mg (30mg on day 1 of cycles
1-4 of CHOP-14 only) was prompted because of the emergence of 2
systemic fungal infections. This led to the reduction in the number of
serious AEs (SAEs) per patient to levels comparable with those seen
within the control arm.37 Although we also observed 2 fungal in-
fections, none were fatal nor counted as DLTs to prompt dose
reduction or expansion. Furthermore, the administration of higher-
dose alemtuzumab in concert with a more cytotoxic chemotherapy
schedule (CHOP-14 not 21) might have compounded toxicity.
Comparisons across the largely phase II studies is difﬁcult because
of the heterogeneous patient populations, doses, schedules, and routes
of alemtuzumab administration, and chemotherapy regimens (see
Supplemental Table 1 in the online version at http://dx.doi.org/10.
1016/j.clml.2015.11.008). In these studies, rates of CMV reac-
tivation ranged from 9% to 54% with CMV infection rates of 5% to
Figure 2 KaplaneMeier Progression-Free (Top) and
Overall Survival (Bottom) Curves From Time of
Enrollment (in Years)
Rena Buckstein et al15%33,34 and treatment-related mortality from 0% to 36%.18,34
Opportunistic infections caused by pathogens associated with severe
T-cell dysfunction including tuberculosis,18,31 John Cunningham
virus,34 PJP,34 CMV,29,31,33 and aspergillosis18,32,34 have all been
reported and some studies did not complete enrollment because of
excess toxicity.29,30,33 It is interesting that Grady et al found that
27% of patients with PTL and cutaneous T cell lymphoma had
CMV viremia before systemic therapy and viral loads correlated with
degrees of CD8þ lymphopenia.38 This suggests that patients with
PTL might be uniquely vulnerable to CMV infections. In our study,
CMV reactivation was a signiﬁcant complication with 3 patients who
received a median of 42 days of valganciclovir because of repeated
activation. However, we did not observe CMV infections nor related
deaths, possibly because of our frequent screening and use of pre-
emptive valganciclovir. We did not implement primary prophylaxis
with valganciclovir,39,40 because of concerns regarding enhanced
myelosuppression. The future prophylactic use of the highly effective
new nonmyelosuppressive antiviral letermovir could be evaluated and
if successful at eliminating CMV reactivation, would greatly simplify
the clinical management of such patients.41Although the degree of T- and B-cell immunosuppression
induced by CHOP-alemtuzumab was expected, the extent of
baseline lymphopenia that preceded chemotherapy (47%) was
greater than reported in diffuse large B cell lymphoma, where it
ranges from 19% to 39%.42-45 This is important to note because
host immunocompetence (as reﬂected by the ALC) might affect the
depths and durations of response to chemotherapy alone43 or with
rituximab in B cell lymphomas.42,44 One cannot know whether
alemtuzumab was responsible for the delay in T-cell recovery after
chemotherapy because it has not been speciﬁcally studied in T-cell
lymphomas. Furthermore, cytotoxic chemotherapy alone might lead
to prolonged periods of T-cell immunosuppression in adults.46,47
Although we did not observe opportunistic infections beyond 3
months, our ﬁndings suggest that more protracted courses of pro-
phylactic antimicrobials and vigilance for virus, fungus, and PJP
might be warranted. In addition, consolidative cellular immuno-
therapy or immunomodulation might be ineffectual in the ﬁrst year
with such degrees of T cell depletion.
To our knowledge, this is the ﬁrst study to measure alemtuzu-
mab PK when used S.C. in combination with chemotherapy in
PTL. In vitro, the concentrations of alemtuzumab required for
complement and antibody dependent cellular cytotoxicity and
apoptosis in CLL range from 0.1 to 10 mg/mL to 0.01 mg/mL,
respectively.48,49 As observed in CLL, we hypothesized that higher
trough concentrations (achievable with higher alemtuzumab doses)
would associate with superior clinical outcomes.24,25,36,50,51
Despite achievement of the highest trough concentrations at 60
mg every 21 days, we observed signiﬁcant interpatient variability
within and between dose levels. For example, at 60 mg dosing,
highest trough levels ranged from 225 ng/mL to 1973 ng/mL in
patients who received 4 doses of alemtuzumab. Peak trough levels
plateaued early in some patients and in others, no plateaus were
seen. The concentrations for dose level 2 were higher than dose
level 3 despite the identical cumulative dose and suggested a
threefold change in clearance and is in agreement with previously
observed nonlinear PK.24 The median terminal half-life was 12 days
but ranged from 3.5 to 58.5 days and was determined in a limited
number of patients. This wide range might be because of the time-
dependent PK of alemtuzumab in which clearance decreases as
tumour burden decreases.24
Only 3 patients achieved the targeted 1 mg/mL reported to be
associated with higher response and minimal residual disease attain-
ment in CLL.36 These differences might be explainable by variations in
tumor burden, intensity of CD52 expression, degrees of immuno-
suppression and soluble CD52. Although we observed no discernable
relationship between peak trough levels and clinical response/dura-
bility, the small sample sizes and different histologies preclude any
decisive conclusions about drug concentration and response.
This phase I study was challenged by slow accrual for 2 major
reasons: drug and patient eligibility on the basis of CD52 expres-
sion. Over the duration of this study, the pharmaceutical ownership
of alemtuzumab changed 3 times, which halted study accrual for
many months as drug supply contracts were renegotiated. At the
time the study was designed, we assumed, on the basis of available
literature speciﬁc to T cells, that CD52 would be expressed on
nearly all mature T-cell lymphomas. Other studies have since
emerged and reported lower incidence of CD52 expression; < 40%Clinical Lymphoma, Myeloma & Leukemia January 2016 - 25
Figure 3 B- and T-Cell Subsets Over Time. Horizontal Dotted Lines Represent Upper and Lower Limits of Normal Reference
Range. (A) CD3/CD8D Suppressor T Cells; (B) CD19D B Cells; (C) CD3D/CD4D T Helper Cells; (D) CD3-CD16DCD56D
Natural Killer Cells (NK Cells). In (C) Only the Lower Limit of Normal is Shown
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26 -to 60% of PTL measured using IHC of parafﬁn-embedded
sections.52,53 Furthermore, CD52 expression appears to vary
according to T cell subtype, the methods used to detect CD52, and
the intensity and/or sites of staining (membranous vs. cytoplasmic)
judged to be positive. Using IHC, the reported rates of CD52
positivity range from 100% for adult T-cell leukemia/lymphoma,
40% for NK/T cell and angioimmunoblastic lymphoma, 35% to
40% for PTL-NOS, and 0% to 22% for ALCL.20,54 The relevance
of CD52 expression intensity using this therapy cannot be answered
by our study but should be explored.
Potential additive beneﬁts of alemtuzumab with CHOP can only
be assessed in a prospective randomized trial. Fortunately, there are
2 phase III studies in the ﬁrst-line setting that are testing alemtu-
zumab 30 mg combined in the ﬁrst 4 cycles of CHOP-14
chemotherapy, and have completed enrollment: ACT-1
(NCT00646854) and ACT-2 (NCT00725231) of the German
and the Nordic lymphoma cooperative study groups, respectively.
Despite selection of an unvalidated dose and schedule of alemtu-
zumab, it is hoped that these studies will more deﬁnitively deter-
mine if there is a survival beneﬁt to this approach.Clinical Lymphoma, Myeloma & Leukemia January 2016Conclusion
The maximally tolerated dose of alemtuzumab with CHOP
chemotherapy is still unknown. With close monitoring for CMV
and the anticipation of enhanced myelosuppression, alemtuzumab
60 mg S.C. every 21 days can be safely administered and achieved
the highest trough levels of all dose levels tested. Lymphopenia at
baseline is common and T-cell lymphopenia is protracted after this
chemoimmunotherapy but its clinical signiﬁcance is currently un-
known. If the recently completed randomized trials establish a signal
of improved survival outcomes compared with CHOP alone,
additional PK studies of 60 mg every 21 days or 20 mg weekly, that
evaluate the relationship between alemtuzumab concentrations,
CD52 expression, and clinical outcomes might still be warranted to
help optimize patient outcomes.
Clinical Practice Points
 Alemtuzumab has been combined with chemotherapy for T-
cell lymphomas in several phase II trials but the safest dose,
trough PK, and immunological effects have not been
studied.
Figure 4 Trough Pharmacokinetics of Alemtuzumab According to Cycle and Dose Level. Y Scale Concentrations Vary According
to Graph. Dose Level 1: Alemtuzumab 10 mg Every 3 Weeks. Dose Level 2: Alemtuzumab 10 mg Weekly. Dose Level 3:
Alemtuzumab 30 mg Every 3 Weeks. Dose Level 4: Alemtuzumab 60 mg Every 3 Weeks
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Rena Buckstein et al In a prospective multicenter phase I study, the maximally
tolerated dose of alemtuzumab was not reached; alemtuzumab
60 mg can be safely combined with CHOP and showed activity
in CD52þ PTL.
 B- and T-cell lymphopenia at baseline is observed in 50% and
70%, respectively, and T-cell lymphopenia is sustained after che-
moimmunotherapy in most patients.
 The highest day 1 alemtuzumab trough levels were achieved at
60 mg (1973 ng/mL), but with signiﬁcant inter- and intradose
variability.
 If alemtuzumab is shown to improve OS in ongoing randomized
trials of aggressive T-cell lymphomas, our ﬁndings might direct
additional research regarding optimal dosing and schedule, and
highlight the importance of sustained antimicrobial therapy after
treatment completion.Acknowledgments
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Appendix A
Patients and Methods
Study Design Monitoring and Steering Committee
A medical monitor at OCOG reviewed all accumulating AEs and
SAEs. The trial steering committee reviewed all AEs and DLTs after
each stage of accrual and before dose level expansion or dose esca-
lation. The trial data were maintained at the OCOG Coordinating
and Methods Centre in Hamilton. The study statistician (G. P.) was
responsible for the analyses. The principal investigator and co-
authors had input into the analyses and preparation of the report.
Measurement of CD52 Using IHC
Primary rat anti-human CD52 antibody (clone YTH34.5;
Serotec, Oxford, United Kingdom; 1:100 dilution) was applied on
formalin-ﬁxed parafﬁn-embedded tissue. Rabbit anti-rat secondary
antibody (Zymed) was applied at a dilution of 1:750. Before anti-
body exposure, the sections underwent enzyme-induced epitope
retrieval using protease 2 (Ventana) for 4 minutes. The CD52 stain
was considered positive when the neoplastic cells exhibited strong
cytoplasmic or membranous staining. Staining in < 30% of the cells
was reported as focally positive. Nuclear staining was considered
nonspeciﬁc and not counted.
Dosing for CHOP Chemotherapy
We used dosages of cyclophosphamide 750 mg/m2 I.V. on day 1,
doxorubicin 50 mg/m2 I.V. on day 1, vincristine 1.4 mg/m2 I.V. (dose
capped at 2 mg) on day 1, and prednisone 100mg orally on days 1 to 5.
Methods of CMV Monitoring
Before August 2008, CMV antigenemia testing was performed
using monoclonal anti-human anti-cytomegalovirus antibodies
directed against pp65 (Biotest Clonal CMV; Biotest) followed by
monoclonal anti-mouse-ﬂuorescein isothiocynate conjugate with
Evans Blue (Baxter). The presence of  1 positive cell per 105
polymorphonuclear cells was reported as positive. In August 2008,
samples were tested using RealStar CMV PCR kits (Astra Di-
agnostics, Hamburg, Germany). The lower limit of detection of the
PCR was 100 copies per mL.
Pharmacokinetics
Serum antibody levels were assayed using a sensitive ELISA
technique (range, 6.3-400 ng/mL) with a precision of 11.1% and an
overall accuracy of 5.3% (Merck Millipore, Discovery & Devel-
opment Solutions, Abingdon, Oxon, United Kingdom).
The elimination half-life was calculated assuming a ﬁrst order
decline in concentrations and standard pharmacokinetic methods
(see Supplemental Table 1 in the online version at http://dx.doi.org/
10.1016/j.clml.2015.11.008).23 Mean trough, and end of interval
concentration time data for patients after dose level 1 was best ﬁt to
a ﬁrst order, 1-compartment model. An assumed ﬁxed time-to-peak
of 3 hours (ka ¼ 1.25 hours  1) and an unchanging bioavailability
(F) was used. This model is insensitive to reasonable variations in
Tmax. The end of interval trough concentrations were best-ﬁt
to standard multiple dose pharmacokinetic equations through a
sum of squares minimization procedure to determine a volume and
half-life.
Anti-Infective Prophylaxis
Granulocyte colony stimulating factor was recommended but not
mandated, unless the patient had a previous episode of febrile
neutropenia.
Toxicity
Patients who had received at least 1 dose of alemtuzumab were
eligible for toxicity assessment. Any AEs that occurred but could not
be categorized according to the CTCAE v3.0 were graded by a
physician and recorded using a scale of (1) mild, (2) moderate, (3)
severe, or (4) life-threatening.
Adverse Event Reporting
After this period, any SAE or Grade 3 to 4 drug-related AEs that
occurred subsequent to the AE reporting period deemed to be
possibly or probably related to the study drug were also
documented.
Statistics
Summary statistics, such as the median, range, and frequency
were used to describe the patient characteristics, overall response
rates, safety proﬁle, and follow-up. The frequency and severity of
all Grade 2 to 5 AEs were summarized according to dose level.
Pharmacokinetic data were conveyed using graphs that depicted
trough levels according to dose level and response and the Wil-
coxon rank sum test was used to explore potential associations
between peak trough levels and response and/or relapse and/or
progression.
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Supplemental Figure 1 Immunoglobulins IgG, IgA, and IgM
Over Time. Dotted Lines Represent the
Upper and Lower Limits of Normal
Supplemental Figure 2 Peak Alemtuzumab Trough Levels
According to Relapse (Top Panel) and
Best Response (Bottom Panel). Labeled
Numbers Represent Median Values
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Abbreviation: Cru ¼ complete remission unconﬁrmed.
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Supplemental Table 1 Summary of Alemtuzumab With CHOP Chemotherapy Studies in T Cell Lymphoma
Reference n
Age
(Range),
Years
Phase Study/
Chemotherapy
Route/
Dose/
Schedule/
Total
Dose/
Cycle
Untreated/
Relapsedor
Refractory CD52D
ORR/CR,
%
Follow-
Up,
Months
EFS/DFS,
% OS
CMV
Reactivation % Infection
TRM,
%
Enblad et al18 14 60 (53-78) 2/None I.V./30
mg/tiw 
12 wk
NA
e/14 No 36/21 e e e 43 Miliary
TB (n ¼ 1),
zoster
(n ¼ 1),
aspergillosis
(n ¼ 2)
36
Janik et al30,a 14 35 (17-77) 1/DA-EPOCH
21
I.V./30/60/90
mg D 1
30/60/90 mg
14/e Yes e/42 e e e 36 Bacterial/
fungal/
viral
(n ¼ 11)
e
Intragumtornchai
et al31
13 44 (21-56) 2/CHOP
21/ESHAP 28
S.C./30
mg/D l-3
cycles
1-5 90 mg
13/e No 90/80
(n ¼ 10
evaluated)
8 75 48% 54 TB (n ¼ 2),
CMV
(n ¼ 1),
FN (n ¼ 7)
e
Kim et al33,b 20 50 (20-65) 2/CHOP-21c I.V./30
mg/D 1
cycles
1-6 30 mg
20/e No 80/65 7 43 1 y 44% 1 y 25 CMV (n ¼ 3),
pseudomonas
pneumonia
(n ¼ 1),
FN (n ¼ 11)
10
Gallamini et al34 25 52 (28-69) 2/CHOP 28 S.C./30
mg/D l cycles
1-8d 30 mg
25/e Yes
11/15 þ
75/71 16 54 1 y,
48 2 y
70% 1 y,
53% 2 y
9 JC virus/
PML (n ¼ 1),
aspergillosis
(n ¼ 2),
PJP (n ¼ l),
staph
aureus
(n ¼ 1)
0
Kim et al28 24 49 (23-60) 2/DHAP 21 I.V./70 mg/40
mg 10 mg
D 1, 30
mg D 1, 2
cycles
1-3,e 70 mg
(n ¼ 16),
40 mg
(n ¼ 8)
0/24 No 50/21 32 e 6 mo 33 CMV
(n ¼ 2),
HBV liver
failure
(n ¼ 1)
8
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Supplemental Table 1 Continued
Reference n
Age
(Range),
Years
Phase Study/
Chemotherapy
Route/
Dose/
Schedule/
Total
Dose/
Cycle
Untreated/
Relapsedor
Refractory CD52D
ORR/CR,
%
Follow-
Up,
Months
EFS/DFS,
% OS
CMV
Reactivation % Infection
TRM,
%
Weidmann
et al29
38 56 (21-77) 2/FCD 21 I.V., S.C.
(l0)/30 mg/10
mg D 1, 30
mg D 2-3
cycles 1-6
70 mg
27/11 No 61/39 17 12 mo,f
2.5 mog
26 mo,f
6 mog
26 FN (n ¼ 15),
CMV (n ¼ 2)
18
Kluin-Nelemans35 20 50 (20-65) 2/CHOP 14 S.C./30
mg D 1,5,
10 cycles
1-8 90 mg
20/0 No 90/65 29 10 mo,
45 1 y,
27 2 y
27 mo 77%
1 y, 55% 2
y
35 FN
(n ¼ 8),
CMV
(n ¼ 1),
EBV and
NHL
(n ¼ 3)
20
Binder et al32 41
29h
55 (19-70) 2/CHOEP 14
age 60
CHOP
14 age >60
I.V./S.C. as
consolidation
D 1-3: 3,
10, 30 mg
I.V. 30 mg
S.C. weekly
 3/133
mg over
4 weeks
consolidation
CR/Cru or
PR patients
only
29/0 No 61/58
(after
chemo)
46 42 3 y 75% 3 y 14 Aspergillus
(n ¼ 1),
Candida
(n ¼ 1),
CMV
(n ¼ 2),
zoster
(n ¼ 1)
0
Abbreviations: ASCT ¼ autologous stem cell transplant; chemo ¼ chemotherapy; CHOEP ¼ cyclophosphamide, adriamycin, vincristine, etoposide and prednisone; CHOP ¼ cyclophosphamide, adriamycin, vincristine and prednisone; CMV ¼ cytomegalovirus; Cru ¼ complete
remission unconﬁrmed; D ¼ day; DA-EPOCH ¼ dose-adjusted infusional etoposide, prednisone, vincristine, cyclophosphamide, and adriamycin; DFS ¼ disease-free survival; DHAP ¼ Dexamethasone, high dose ara-C and cisplatin; EBV ¼ Ebstein-Barr virus; EFS ¼ event-free
survival; ESHAP ¼ etoposide, high-dose cytarabine and cisplatin; FCD ¼ ﬂudarabine, cyclophosphamide and doxorubicin; FN ¼ febrile neutropenia; HBV ¼ hepatitis B virus; JC ¼ John Cunningham; NHL ¼ non-Hodgkinapos;s lymphoma; OS ¼ overall survival; PJP ¼
pneumocystis jiroveci pneumonia; PML ¼ progressive multifocal leukoencephalopathy; S.C. ¼ subcutaneous; TB ¼ tuberculosis; tiw = three times weekly; TRM ¼ treatment-related mortality.
aAbstract only: bone marrow suppression prevented further treatment at 60 mg dose cycles 3, and 5 (n ¼ 2) and 90 mg at cycles 4, and 5 (n ¼ 2).
bThe study closed earlier than the planned with 43 patients because of infectious complications.
cASCT in 4 patients followed.
dFor the ﬁrst 4 patients, alemtuzumab given only for 4 cycles.
eFirst 16 patients received 30 mg on D 2 as well, total dose 70 mg; 8 responders went on to ASCT.
fNew diagnosis.
gRelapsed refractory.
hReceived alemtuzumab as consolidation.
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